NCT01925417View on ClinicalTrials.gov

Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

July 31, 2014

Conditions
Recurrent Clostridium Difficile Infection
Interventions
BIOLOGICAL

RBX2660 (microbiota suspension)

Trial Locations (13)

20815

Chevy Chase Clinical Research, Chevy Chase

32216

Borland-Groover Clinic, Jacksonville

48201

Detroit Medical Center, Detroit

48202

Henry Ford Health System, Detroit

55905

Mayo Clinic - Minnesota, Rochester

58122

Sanford Research/USD, Fargo

60141

Edward Hines Jr VA Hospital (veterans only), Chicago

60637

University of Chicago, Chicago

63110

Washington University, St Louis

70121

Ochsner Clinic, New Orleans

80204

Denver Health and University of Colorado, Denver

85054

Mayo Clinic Arizona, Phoenix

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

Rebiotix Inc.

INDUSTRY

NCT01925417 - Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea | Biotech Hunter | Biotech Hunter